In animal reproduction studies, adverse effects on development were observed following intranasal administration of dihydroergotamine mesylate during pregnancy (decreased fetal body weight and/or skeletal ossification) in rats and rabbits or during pregnancy and lactation in rats (decreased body weight and impaired reproductive function in the offspring) at doses that were not associated with maternal toxicity (see Data)
Mutations in the MTHFR genes (specifically 677 and 1298) can disrupt this cycle
Products designated as Research & Development (R&D) Only are intended exclusively for experimental, analytical, and educational purposes and are not approved as medicines, foods, cosmetics, dietary supplements, or consumer wellness products
This is why BPC-157 research expanded from tissue healing into psychiatry and neurogastroenterology
FDA status Neither TB-500 nor BPC-157 is FDA-approved for human therapeutic use
Swirl or roll gently until fully dissolved dont shake hard